Citations (78)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Juan Javier Servat, Katrina A Mears, Evan H Black & John J Huang. (2012) Biological agents for the treatment of uveitis. Expert Opinion on Biological Therapy 12:3, pages 311-328.
Read now
Read now
Marina Talamonti, Giulia Spallone, Alessandro Di Stefani, Antonio Costanzo & Sergio Chimenti. (2011) Efalizumab. Expert Opinion on Drug Safety 10:2, pages 239-251.
Read now
Read now
Jennifer D Bahner, Lauren Y Cao & Neil J Korman. (2009) Biologics in the management of psoriasis. Clinical, Cosmetic and Investigational Dermatology 2, pages 111-128.
Read now
Read now
Bishoy Faltas & Zachary B. Kramer. (2009) Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori. Leukemia & Lymphoma 50:9, pages 1538-1539.
Read now
Read now
Rupa Pugashetti & John Koo. (2009) Efalizumab discontinuation: A practical strategy. Journal of Dermatological Treatment 20:3, pages 132-136.
Read now
Read now
Francesca Prignano, F Zanieri, S Mokhtarzadeh & T Lotti. (2008) Efalizumab-induced severe thrombocytopenia can be resolved. Biologics: Targets and Therapy 2:4, pages 923-927.
Read now
Read now
F.M. Pherez & B.A. Cunha. (2008) Fever of Unknown Origin (FUO) Due to Efalizumab, an Immunomodulating Agent. Journal of Chemotherapy 20:3, pages 387-387.
Read now
Read now
Sandra Philipp, Kerstin Wolk, Stephanie Kreutzer, Elizabeth Wallace, Nina Ludwig, Joachim Roewert, Conny Höflich, Hans-Dieter Volk, Wolfram Sterry & Robert Sabat. (2006) The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opinion on Therapeutic Targets 10:6, pages 817-831.
Read now
Read now
Articles from other publishers (70)
Jiangwei Ni, Ge Li, Ningfeng Dai, Zijiao Quan, Haibin Tong & Yu Liu. (2023) Esculin alleviates LPS-induced acute lung injury via inhibiting neutrophil recruitment and migration. International Immunopharmacology 119, pages 110177.
Crossref
Crossref
Liisa M. Uotila, Heidi Harjunpää & Susanna C. Fagerholm. 2023. Integrins in Health and Disease. Integrins in Health and Disease
309
356
.
Tiantian Hu, Zhan Zhang, Chunbo Deng, Xun Ma & Xueyong Liu. (2022) Effects of β2 Integrins on Osteoclasts, Macrophages, Chondrocytes, and Synovial Fibroblasts in Osteoarthritis. Biomolecules 12:11, pages 1653.
Crossref
Crossref
Eleftheria E. Kampouri, Jonathan Tschopp & Oriol Manuel. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
253
272
.
Wen-Wei Lin, Yun-Chi Lu, Chih-Hung Chuang & Tian-Lu Cheng. (2020) Ab locks for improving the selectivity and safety of antibody drugs. Journal of Biomedical Science 27:1.
Crossref
Crossref
Heidi Harjunpää, Marc Llort Asens, Carla Guenther & Susanna C. Fagerholm. (2019) Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment. Frontiers in Immunology 10.
Crossref
Crossref
Germán Morís & Juan Carlos García-Moncó. 2018. CNS Infections. CNS Infections
275
300
.
Javier Alfaro, Dolores P?rez, Carlos Jim?nez, Manuel Serrano, Jos? ?ngel Mart?nez-Flores, Montserrat Grau, Elena S?nchez-Zapardiel, Estela Paz-Artal & Antonio Serrano. (2016) Blockade of cell adhesion molecules enhances cell engraftment in a murine model of liver cell transplantation. Transplant Immunology 35, pages 7-11.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
20
24
.
Manoranjenni Chetty, Linzhong Li, Rachel Rose, Krishna Machavaram, Masoud Jamei, Amin Rostami-Hodjegan & Iain Gardner. (2015) Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Frontiers in Immunology 5.
Crossref
Crossref
Germán Morís & Juan Carlos García-Moncó. 2014. CNS Infections. CNS Infections
249
271
.
Adrian Reuben. 2013. Drug-Induced Liver Disease. Drug-Induced Liver Disease
569
591
.
Janet E Angus, Ray Jobling, Hywel C Williams, Ingvil Saeterdal, Catherine Roberts & Elmer Villanueva. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Ronni Wolf, Jasna Lipozenčić & Batya B. Davidovici. 2011. Emergency Dermatology. Emergency Dermatology
168
177
.
Roberto Carreño, Wells S. Brown, Dan Li, Jessica A. Hernandez, Yang Wang, Tae Kon Kim, John W. CraftJrJr, Krishna V. Komanduri, Laszlo G. Radvanyi, Patrick Hwu, Jeffrey J. Molldrem, Glen B. Legge, Bradley W. McIntyre & Qing Ma. (2010) 2E8 Binds to the High Affinity I-domain in a Metal Ion-dependent Manner. Journal of Biological Chemistry 285:43, pages 32860-32868.
Crossref
Crossref
. (2010) Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma & Immunology 105:4, pages 259-273.e78.
Crossref
Crossref
A.M Posselt, M.D Bellin, M. Tavakol, G.L Szot, L.A Frassetto, U. Masharani, R.K Kerlan, L. Fong, F.G Vincenti, B.J Hering, J.A Bluestone & P.G Stock. (2010) Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab. American Journal of Transplantation 10:8, pages 1870-1880.
Crossref
Crossref
S. M. Breathnach. 2010. Rook's Textbook of Dermatology. Rook's Textbook of Dermatology
1
177
.
Tu Anh Duong, Valérie Buffard, Chantal André, Nicolas Ortonne, Jean Revuz, Martine Bagot & Jean-Claude Roujeau. (2010) Efalizumab-induced bullous pemphigoid. Journal of the American Academy of Dermatology 62:1, pages 161-162.
Crossref
Crossref
Joaquín Primo, Joaquín Michavila & Iratxe Jiménez. (2010) Hepatitis autoinmunitaria inducida por efalizumab. Gastroenterología y Hepatología 33:1, pages 69-70.
Crossref
Crossref
Carlos Ferrándiz, Jose Manuel Carrascosa & Aram Boada. (2010) A new era in the management of psoriasis? The biologics: facts and controversies. Clinics in Dermatology 28:1, pages 81-87.
Crossref
Crossref
Heinz Wiendl, Nico Melzer, Christoph Kleinschnitz & Sven G. Meuth. 2010. MULTIPLE SCLEROSIS 3. MULTIPLE SCLEROSIS 3
388
426
.
Rebecca G. Pomerantz, Thomas S. Kupper & Abrar A. Qureshi. 2010. Therapy of Skin Diseases. Therapy of Skin Diseases
29
38
.
Alice B. Gottlieb & Frank Dann. (2009) Comorbidities in Patients with Psoriasis. The American Journal of Medicine 122:12, pages 1150.e1-1150.e9.
Crossref
Crossref
D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, JD Bos, G-R Burmester, S Chimenti, L Dubertret, B Eberlein, R Erdmann, J Ferguson, G Girolomoni, P Gisondi, A Giunta, C Griffiths, H Hönigsmann, M Hussain, R Jobling, S-L Karvonen, L Kemeny, I Kopp, C Leonardi, M Maccarone, A Menter, U Mrowietz, L Naldi, T Nijsten, J-P Ortonne, H-D Orzechowski, T Rantanen, K Reich, N Reytan, H Richards, HB Thio, P van de Kerkhof & B Rzany. (2009) European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 23, pages 1-70.
Crossref
Crossref
N. Kluger, C. Heroum, C. Michot, B. Guillot & D. Bessis. (2009) Migraine with aura induced by efalizumab. Clinical and Experimental Dermatology 34:7, pages e401-e402.
Crossref
Crossref
Robert Bissonnette, Vincent Ho & Richard G. Langley. (2009) Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis. Journal of Cutaneous Medicine and Surgery 13:5_suppl, pages S67-S76.
Crossref
Crossref
Yang Wang, Dan Li, Roza Nurieva, Justin Yang, Mehmet Sen, Roberto Carreño, Sijie Lu, Bradley W. McIntyre, Jeffrey J. Molldrem, Glen B. Legge & Qing Ma. (2009) LFA-1 Affinity Regulation Is Necessary for the Activation and Proliferation of Naive T Cells. Journal of Biological Chemistry 284:19, pages 12645-12653.
Crossref
Crossref
M. Caproni, W. Volpi, C. Chiarini, E. Antiga, B. Giomi & P. Fabbri. (2009) A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis. British Journal of Dermatology 160:4, pages 896-897.
Crossref
Crossref
Efstathios Rallis, Constantinos Verros, Evmorfia Karanikola, Argyro Valaskatzi & Markos Papaconstantis. (2009) Exacerbation of Psoriasis under Efalizumab Therapy. Journal of Cutaneous Medicine and Surgery 13:2, pages 106-109.
Crossref
Crossref
Sadia Ashraf-Benson, Geoffrey C Wall & Lisa A Veach. (2009) Serum Sickness–Like Reaction Associated with Efalizumab. Annals of Pharmacotherapy 43:2, pages 383-386.
Crossref
Crossref
Kazuyoshi SAITO & Yoshiya TANAKA. (2009) New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Japanese Journal of Clinical Immunology 32:3, pages 149-159.
Crossref
Crossref
Xinaida T. Lima, Elizabeth M. Seidler, Hermênio C. Lima & Alexandra B. Kimball. (2009) Long-term safety of biologics in dermatology. Dermatologic Therapy 22:1, pages 2-21.
Crossref
Crossref
F.A. Goumas, F. Braun, D.C. Broering & M. Behrend. 2009.
589
618
.
Josep Manel Casanova, Verónica Sanmartín, Xavier Soria, Marta Ferran, Ramon M. Pujol & Miquel Ribera. (2009) Tratamiento de la psoriasis en placas moderada y grave con efalizumab. Piel 24:1, pages 52-57.
Crossref
Crossref
Brittney Culp & M Menter. 2008. Moderate-to-Severe Psoriasis, Third Edition. Moderate-to-Severe Psoriasis, Third Edition
307
326
.
Iain David O’Neill. (2008) Off-label use of biologicals in the management of inflammatory oral mucosal disease. Journal of Oral Pathology & Medicine 37:10, pages 575-581.
Crossref
Crossref
A Nast, N Reytan, S Rosumeck, R Erdmann & B Rzany. (2008) Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. Journal of the European Academy of Dermatology and Venereology 22:11, pages 1337-1342.
Crossref
Crossref
Benedetta Belloni, Christian Andres, Markus Ollert, Johannes Ring & Martin Mempel. (2008) Novel immunological approaches in the treatment of atopic eczema. Current Opinion in Allergy & Clinical Immunology 8:5, pages 423-427.
Crossref
Crossref
D. Thaçi. (2008) Long-term data in the treatment of psoriasis. British Journal of Dermatology 159, pages 18-24.
Crossref
Crossref
Jeanine L. Bussiere & Barbara Mounho. 2008. Immunotoxicology Strategies for Pharmaceutical Safety Assessment. Immunotoxicology Strategies for Pharmaceutical Safety Assessment
189
198
.
Julia M. Kwan, Amy M. Reese & John P. Trafeli. (2008) Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. Journal of the American Academy of Dermatology 58:6, pages 1053-1055.
Crossref
Crossref
Manuelle Viguier, Pascal Richette, François Aubin, Marie Beylot-Barry, Morad Lahfa, Christophe Bedane, Franck Delesalle, Marie-Aleth Richard-Lallemand, Emmanuel Delaporte, Louis Dubertret, Thomas Bardin & Hervé Bachelez. (2008) Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis & Rheumatism 58:6, pages 1796-1802.
Crossref
Crossref
E. Rallis, P. Tapinis & C.D. Verros. (2008) Efalizumab-induced hypertrichosis. British Journal of Dermatology 158:5, pages 1158-1159.
Crossref
Crossref
Alan Menter, Alice Gottlieb, Steven R. Feldman, Abby S. Van Voorhees, Craig L. Leonardi, Kenneth B. Gordon, Mark Lebwohl, John Y.M. Koo, Craig A. Elmets, Neil J. Korman, Karl R. Beutner & Reva Bhushan. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 58:5, pages 826-850.
Crossref
Crossref
Maria Concetta Fargnoli, Antonio Tabilio, Gino Coletti & Ketty Peris. (2008) Efalizumab-induced immune thrombocytopenia during retreatment. Journal of the American Academy of Dermatology 58:5, pages S125-S127.
Crossref
Crossref
A. Nosbaum, C. Allombert-Blaise, A. Ly, D. Jullien, M. Faure, A. Claudy & M. Simon. (2008) Pancytopénie au cours d’un traitement par efalizumab. Annales de Dermatologie et de Vénéréologie 135:5, pages 407-408.
Crossref
Crossref
TF Tsai, MT Liu, YH Liao & D Licu. (2008) Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. Journal of the European Academy of Dermatology and Venereology 22:3, pages 345-352.
Crossref
Crossref
Kazuyoshi Saito & Yoshiya Tanaka. (2008) 7. Recent Topics on New Biological Agents for Treatment of Rheumatoid Arthritis. Nihon Naika Gakkai Zasshi 97:10, pages 2418-2423.
Crossref
Crossref
Steven R Barthel, Mats W Johansson, Dawn M McNamee & Deane F Mosher. (2008) Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. Journal of Leukocyte Biology 83:1, pages 1-12.
Crossref
Crossref
J.M. Carrascosa. (2008) Estrategias para optimizar el tratamiento con efalizumab. Actas Dermo-Sifiliográficas 99, pages 37-50.
Crossref
Crossref
J.L. Sánchez Carazo, L. Martínez Casimiro & V. Alegre de Miguel. (2008) Es necesario el control de la psoriasis a largo plazo. Actas Dermo-Sifiliográficas 99, pages 29-36.
Crossref
Crossref
E. Daudén & M.J. Oñate. (2008) Efalizumab: ¿un tratamiento seguro para una enfermedad crónica?. Actas Dermo-Sifiliográficas 99, pages 18-28.
Crossref
Crossref
Caroline P. Halverstam. (2018) Practical Management and Monitoring of Psoriasis Patients on Biologic Therapy: A Survey of Opinion Leaders and Practitioners. Psoriasis Forum 13a:2, pages 4-12.
Crossref
Crossref
J. M. L. White, C. H. Smith, A. Robson, G. Ash & J. N. W. N. Barker. (2007) DRESS syndrome caused by efalizumab. Clinical and Experimental Dermatology 0:0, pages 071117034640005-???.
Crossref
Crossref
Sarah Grim Hostetler, Matthew Zirwas & Mark A. Bechtel. (2007) Efalizumab-associated thrombocytopenia. Journal of the American Academy of Dermatology 57:4, pages 707-710.
Crossref
Crossref
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier & H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen AnsätzenUpdate on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis. Der Nervenarzt 78:8, pages 883-911.
Crossref
Crossref
Harold J. Burstein. (2007) Aromatase inhibitor-associated arthralgia syndrome. The Breast 16:3, pages 223-234.
Crossref
Crossref
Markus B?hm & Thomas A. Luger. (2007) Lichen planus responding to efalizumab. Journal of the American Academy of Dermatology 56:5, pages S92-S93.
Crossref
Crossref
A. Costanzo, K. Peris, M. Talamonti, A. Di Cesare, M. Concetta Fargnoli, E. Botti & S. Chimenti. (2007) Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. British Journal of Dermatology 156:s2, pages 17-23.
Crossref
Crossref
N. Selenko-Gebauer, F. Karlhofer & G. Stingl. (2007) Efalizumab in routine use: a clinical experience. British Journal of Dermatology 156:s2, pages 1-6.
Crossref
Crossref
James B. Bussel, Lisa Giulino, Susan Lee, Vivek L. Patel, Christy Sandborg & E. Richard Stiehm. (2007) Update on Therapeutic Monoclonal Antibodies. Current Problems in Pediatric and Adolescent Health Care 37:4, pages 118-135.
Crossref
Crossref
Jeffrey P. Callen. (2007) Complications and Adverse Reactions in the Use of Newer Biologic Agents. Seminars in Cutaneous Medicine and Surgery 26:1, pages 6-14.
Crossref
Crossref
Monica Lawry. (2007) Biological therapy and nail psoriasis. Dermatologic Therapy 20:1, pages 60-67.
Crossref
Crossref
N. Kluger, C. Girard, V. Gonzalez, B. Guillot & D. Bessis. (2007) Efalizumab-induced aseptic meningitis. British Journal of Dermatology 156:1, pages 189-191.
Crossref
Crossref
Martin Röcken & Christina Weigert. 2007. Fortschritte der praktischen Dermatologie und Venerologie 2006. Fortschritte der praktischen Dermatologie und Venerologie 2006
41
51
.
John M. Vierling. 2007. Liver Immunology. Liver Immunology
391
407
.
Heinz Wiendl & Reinhard Hohlfeld. 2007. Immune Regulation and Immunotherapy in Autoimmune Disease. Immune Regulation and Immunotherapy in Autoimmune Disease
289
338
.
Kim A Papp, Darryl Toth & Les Rosoph. (2006) Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatology 6:1.
Crossref
Crossref
V. Descamps. (2006) Efalizumab. Annales de Dermatologie et de V?n?r?ologie 133:8-9, pages 666-678.
Crossref
Crossref